De Toni EN, Schlesinger-Raab A, Fuchs M, et al. - This study was undertaken to determine if the implementation of screening policies and the improvement of treatment options translated into a real-world survival benefit in patients (n = 4,078) diagnosed with hepatocellular carcinoma (HCC), the major cause of death worldwide. Between 1998 and 2016, HCC patients from the Munich Cancer Registry have been analyzed. Data reported that the 3 years RS in HCC improved from 19.8% in 1998–2002, 22.4% in 2003–2007, 30.6% in 2008–2012 up to 31.0% in 2013–2016. Between 1998–2002 and 2008–2016, median OS increased from 6 months to 12 months. Findings revealed that there was no increase in the incidence of HCC in the representative German region in contrast to the current hypotheses. Earlier detection, linked to screening programmes implementation, translated into increasing employment of effective therapeutic options and a clear survival benefit in individuals without metastases at diagnosis, regardless of age.